The Future of Stem Cell Therapy for Stroke Rehabilitation

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

CV Borlongan is supported by research funds from the National Institute of Health, US Department of Defense, VA Merit Review, James and Esther King, SanBio, KM Pharmaceuticals, Neuralstem and Karyopharm Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

CV Borlongan is supported by research funds from the National Institute of Health, US Department of Defense, VA Merit Review, James and Esther King, SanBio, KM Pharmaceuticals, Neuralstem and Karyopharm Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Notes on contributors

Cesar V Borlongan

Cesar V Borlongan is a distinguished professor and vice chairman for research at the University of South Florida Morsani College of Medicine in the Department of Neurosurgery and Brain Repair. He is a world leader in stem cell research for stroke therapy, with his highly innovative translational bench-to-bed approach facilitating the initiation of US FDA-approved clinical trials of cell transplantation in neurological disorders, including the world's first cell therapy in stroke patients.

Jukka Jolkkonen

Jukka Jolkkonen is an Adjunct Professor at the University of Eastern Finland. His main interest has been on translational stroke recovery and particularly on how to enhance brain plasticity and how best to assess the functional outcome in experimental animals. He is the co-editor with Piotr Walczak of the book Cell-Based Therapies in Stroke.

Olivier Detante

Olivier Detante is a neurologist at the Grenoble University Hospital (France) and Associate Professor at the Grenoble Alpes University. His main interest is stroke care and recovery, and clinical development of cell therapy for stroke. As visiting associate professor at the Institute of Regenerative Medicine of Kyoto University, he studied reparative biomaterials combined with cell therapy for stroke. He is the principal investigator of the French clinical trial about autologous cell therapy after stroke.